Profusa converts $4.6M debt to preferred stock ahead of G3 deal

Profusa (PFSA) secured $10.7M of Series A Convertible Exchange Agreements, converting $4.57M into 4,271,298 shares of Series A Convertible Preferred Stock, while completing a 4:1 reverse split and executing an Option Agreement to acquire G3 Vision Labs. Despite the recapitalization steps, losses widened with net loss of $8.8M for the quarter ended June 30, 2026 (vs. $2.3M a year earlier) and $12.2M for the first six months of 2026 (vs. $5.1M in 2025), alongside $28.2M current liabilities and $28.2M total liabilities. The company said these actions support meeting Nasdaq’s minimum listing requirements, and reported $719k cash and $1.0M total assets as of June 30, 2026.

Analysis

This is less a fundamentals story than a balance-sheet reset with a very high probability of further dilution. Converting creditor claims into equity can make the headline equity picture look healthier, but it does not create cash flow; it simply shifts value from lenders to a much larger post-split common base. For microcap healthcare names, that usually means any compliance-driven bounce is a financing window for insiders and legacy holders, not a durable re-rating.

The real catalyst path is binary over the next 2-8 weeks: audited financials and the G3 process either de-risk the listing issue or expose that the company still needs outside capital to survive. If the audit slips past mid-September or the acquisition is delayed, expect renewed pressure from short sellers and market makers because the stock now has all the ingredients of a classic post-reverse-split fade. The operational bridge is also weak: cash is thin relative to liabilities, so even a successful close likely just buys time rather than changing unit economics.

Second-order, the only plausible winners are the creditors who converted at terms that preserve optionality and any vendors or counterparties tied to a going-concern rescue. The losers are common equity holders, who face serial issuance risk and poor liquidity; the move can also trap passive holders because the post-split float is usually smaller but more fragile. The contrarian view is that if the CLIA lab assets are real and auditable, the market may be underestimating residual private-market value, but that thesis needs proof in the form of clean filings and a financing announcement, not press-release optics.

Key Decisions for Investors

• Avoid initiating a long in PFSA until audited statements are filed and the G3 transaction clears; the expected risk/reward is still negative because dilution and financing risk dominate near-term fundamentals.
• If PFSA rallies on reverse-split/compliance headlines, consider a tactical short only with confirmed borrow and tight risk controls; thesis fails if audited filings land on time and management announces non-dilutive capital.
• Watch PFSA as a binary event trade into mid-September: a clean audit plus financing could support a brief squeeze, but absent both, the stock is likely a fade candidate after the technical window closes.
• Do not express this through NDAQ or DJT; there is no meaningful second-order fundamental link for those names from this filing.